Real-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)

dc.authorscopusid37002887000
dc.authorscopusid16203384500
dc.authorscopusid57867202100
dc.authorscopusid7005094713
dc.authorscopusid7003953248
dc.authorscopusid56348383300
dc.authorscopusid6603070081
dc.contributor.authorKayikci, Omur
dc.contributor.authorMehtap, Ozgur
dc.contributor.authorSari, Ismail
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorBeyan, Cengiz
dc.contributor.authorCetin, Guven
dc.contributor.authorVural, Filiz
dc.date.accessioned2023-01-12T20:16:53Z
dc.date.available2023-01-12T20:16:53Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event-free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy.en_US
dc.identifier.doi10.4274/tjh.galenos.2022.2022.0052
dc.identifier.endpage177en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue3en_US
dc.identifier.pmid35678126en_US
dc.identifier.scopus2-s2.0-85137000431en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage170en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2022.2022.0052
dc.identifier.urihttps://hdl.handle.net/11454/78787
dc.identifier.volume39en_US
dc.identifier.wosWOS:000883473800003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLymphomasen_US
dc.subjectAutologous stem cell transplantationen_US
dc.subjectT-cell lymphomasen_US
dc.subjectNon-Hodgkin lymphomaen_US
dc.subjectHigh-Dose Chemotherapyen_US
dc.subjectAmerican Societyen_US
dc.subjectUp-Fronten_US
dc.subjectTransplantationen_US
dc.subjectSurvivalen_US
dc.subjectGuidelinesen_US
dc.subjectPrognosisen_US
dc.subjectDiseaseen_US
dc.subjectCohorten_US
dc.titleReal-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)en_US
dc.title.alternativeNon-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışmasıen_US
dc.typeArticleen_US

Dosyalar